GlassScriptPhysician profile
Thomas Bumbalo
NPI 1386759488
$5,361.87
in general payments reported to CMS, 2019-2025
30 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $155 · 2021: $279 · 2022: $1,786 · 2023: $772 · 2024: $157 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866 · Travel and Lodging: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.12 |
| Travel and Lodging | $282.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $2,010.04 | 2019-2025 | Monarch Platform |
| Glaxosmithkline, LLC. | $705.32 | 2019-2024 | Nucala, Trelegy Ellipta |
| Veran Medical Technologies, INC. | $426.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $297.12 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.86 | 2019-2023 | Ofev |
| Abbott Laboratories | $251.60 | 2022-2023 | Freestyle Libre 3 |
| Genzyme Corporation | $239.96 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $144.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $139.24 | 2019-2020 | |
| Astellas Pharma US INC | $134.00 | 2019 | |
| Insmed, INC. | $108.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.39 | 2019-2024 | Tezspire |
| Philips North America LLC | $75.03 | 2019-2023 | |
| United Therapeutics Corporation | $68.12 | 2019-2025 | Tyvaso |
| Grifols USA, LLC | $61.86 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60.10 | 2022-2023 | Teflaro |
| Gilead Sciences, INC. | $46.26 | 2023-2024 | Veklury |
| Intuitive Surgical, INC. | $24.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.29 | 2023 | Nuzyra |
| Genentech USA, INC. | $20.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.52 | 2022 | |
| Mylan Specialty L.P. | $19.36 | 2024 | Yupelri |
| Viatris Specialty LLC | $18.72 | 2025 | Yupelri |
| Shire North American Group INC | $18.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.93 | 2019 | |
| Nabriva Therapeutics, Plc | $14.33 | 2020 | |
| Allergan, INC. | $11.20 | 2019 | |
| Biomerieux INC | $8.68 | 2019 | |
| Sumitomo Pharma America, INC. | $2.09 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bumbalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.